| Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA. (NCT06659692) | IBSA Institut Biochimique SA | 2024-09-23 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) (NCT06384560) | Amsterdam UMC, location VUmc | 2024-09-23 |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (NCT06284486) | M.D. Anderson Cancer Center | 2024-09-23 |
| DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial (NCT06492707) | Fred Hutchinson Cancer Center | 2024-09-23 |
| A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men (NCT06649630) | Novo Nordisk A/S | 2024-09-23 |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (NCT06413680) | Regeneron Pharmaceuticals | 2024-09-23 |
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer (NCT06555796) | Amgen | 2024-09-23 |
| Bioequivalence Study of Generic Celecoxib 200 mg Capsules (NCT06337422) | International Bio service | 2024-09-23 |
| Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. (NCT06634927) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2024-09-22 |
| Target-specific immunoPET Imaging of Breast Cancer (NCT06715826) | RenJi Hospital | 2024-09-21 |
| U87 CAR-T in Patients With Advanced Head and Neck Tumors (NCT06614686) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2024-09-20 |
| A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function (NCT07625618) | Wuhan Createrna Science and Technology Co., Ltd | 2024-09-20 |
| A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors (NCT06598007) | Crossignal Therapeutics, Inc. | 2024-09-20 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (NCT06483048) | Mayo Clinic | 2024-09-20 |
| A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD (NCT06600425) | ReCode Therapeutics | 2024-09-20 |
| A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment (NCT06539338) | Kite, A Gilead Company | 2024-09-20 |
| Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis (NCT05860569) | GeneCradle Inc | 2024-09-20 |
| A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) (NCT06575959) | Merck Sharp & Dohme LLC | 2024-09-20 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (NCT06469944) | Merck Sharp & Dohme LLC | 2024-09-20 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (NCT06607692) | Fundación de investigación HM | 2024-09-20 |
| The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function (NCT06562946) | Abbisko Therapeutics Co, Ltd | 2024-09-20 |
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (NCT06193759) | Children's National Research Institute | 2024-09-20 |
| A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease (NCT06557850) | H. Lundbeck A/S | 2024-09-19 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors (NCT06586957) | NiKang Therapeutics, Inc. | 2024-09-19 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (NCT06561685) | Eli Lilly and Company | 2024-09-19 |
| A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) (NCT06566989) | Merck Sharp & Dohme LLC | 2024-09-19 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. (NCT06927466) | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | 2024-09-19 |
| (2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain (NCT05864053) | Rush University Medical Center | 2024-09-19 |
| ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (NCT06254326) | University of Florida | 2024-09-19 |
| Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns (NCT05856994) | Vanderbilt University Medical Center | 2024-09-19 |
| A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants (NCT06568458) | Bristol-Myers Squibb | 2024-09-19 |
| Blinatumomab for CNI-Resistant/Intolerant SRNS in Children (NCT06607991) | The Children's Hospital of Zhejiang University School of Medicine | 2024-09-19 |
| Phase 1 Study of ART5803 in Healthy Participants (NCT06575153) | Arialys Therapeutics | 2024-09-19 |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (NCT06291987) | University of Chicago | 2024-09-19 |
| A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (NCT06619951) | Jiangsu vcare pharmaceutical technology co., LTD | 2024-09-18 |
| Topical ENS-002 for Atopic Dermatitis in Adults (NCT06469385) | Concerto Biosciences | 2024-09-18 |
| Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions (NCT06569381) | Overseas Pharmaceuticals, Ltd. | 2024-09-18 |
| NS-050/NCNP-03 in Boys With DMD (Meteor50) (NCT06053814) | NS Pharma, Inc. | 2024-09-18 |
| Pacritinib in CMML (NCT06159491) | Douglas Tremblay | 2024-09-18 |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (NCT06542250) | AstraZeneca | 2024-09-18 |
| A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer (NCT06632964) | The Affiliated Hospital of Xuzhou Medical University | 2024-09-18 |
| A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 (NCT06597656) | Sarepta Therapeutics, Inc. | 2024-09-18 |
| Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy (NCT06369974) | Massachusetts General Hospital | 2024-09-18 |
| A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years (NCT06562985) | Bayer | 2024-09-18 |
| Study to Evaluate HT-4253 in Healthy Subjects (NCT06537817) | Halia Therapeutics, Inc. | 2024-09-17 |
| Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD) (NCT06638879) | Children's Hospital Medical Center, Cincinnati | 2024-09-17 |
| A Study to Assess NEU-111 in Healthy Participants (NCT06500442) | Neuron23 Inc. | 2024-09-17 |
| A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants (NCT06504043) | Hasten Biopharmaceutical Co., Ltd. | 2024-09-17 |
| A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants (NCT06627556) | Jiangsu Carephar Pharmaceutical Co., Ltd. | 2024-09-17 |
| Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (NCT06560632) | Repare Therapeutics | 2024-09-17 |
| Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older (NCT06604767) | Sanofi Pasteur, a Sanofi Company | 2024-09-17 |
| Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs (NCT06567015) | Pierre Fabre Medicament | 2024-09-17 |
| Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). (NCT06333951) | Amgen | 2024-09-17 |
| Open-Label Study of Safety of H1337 in Healthy Volunteers (NCT06572397) | D. Western Therapeutics Institute, Inc. | 2024-09-16 |
| A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors (NCT06537310) | Hoffmann-La Roche | 2024-09-16 |
| Graded Insulin Suppression Test P&F (NCT06592261) | Columbia University | 2024-09-16 |
| A Study of VET3-TGI in Patients With Solid Tumors (NCT06444815) | KaliVir Immunotherapeutics | 2024-09-16 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity (NCT06679959) | Ascletis Pharma (China) Co., Limited | 2024-09-16 |
| A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) (NCT06526923) | Spirovant Sciences, Inc. | 2024-09-16 |
| Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans (NCT06058702) | Yale University | 2024-09-16 |
| Bioequivalence Test of Hemay005 Tablets (NCT06610903) | Ganzhou Hemay Pharmaceutical Co., Ltd | 2024-09-15 |
| A Pilot Bioequivalence Study of Pomalidomide (NCT06058689) | Megalabs | 2024-09-15 |
| Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA (NCT06781957) | IBSA Institut Biochimique SA | 2024-09-15 |
| Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease (NCT05623501) | University of Southern California | 2024-09-15 |
| A Clinical Study to Evaluate the Safety and Efficacy of JHM03 in Adult Patients With Upper Limb Spasticity (NCT06584240) | JHM BioPharma (Tonghua) Co. , Ltd. | 2024-09-14 |
| Self-acupuncture for Migraines Feasibility Study (NCT06716944) | University of West London | 2024-09-13 |
| A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (NCT06207123) | University of Chicago | 2024-09-13 |
| A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine (NCT06578585) | H. Lundbeck A/S | 2024-09-13 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy (NCT06388707) | NaviFUS Corporation | 2024-09-13 |
| Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants (NCT06577337) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-09-12 |
| E-CEL UVEC Treatment for Anal Fissures (NCT06456073) | Weill Medical College of Cornell University | 2024-09-12 |
| Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites (NCT06759064) | Qilu Hospital of Shandong University | 2024-09-12 |
| A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants (NCT06411860) | Amgen | 2024-09-12 |
| A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) (NCT06575400) | Boehringer Ingelheim | 2024-09-12 |
| Pilot Study of the α Prototype NIMBLE System: Feasibility, Safety, and Initial Performance in Non-Invasive Detection of Coronary In-Stent Restenosis (NCT06968858) | Nimble Diagnostics S.L. | 2024-09-12 |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (NCT06586515) | Eli Lilly and Company | 2024-09-12 |
| A Phase I Clinical Trial to Evaluate CU-10101 Unguent (NCT06744569) | Cutia Therapeutics（Wuxi）Co.,Ltd | 2024-09-12 |
| A Study of Exercise Therapy in People With Solid Tumor Cancer (NCT06597786) | Memorial Sloan Kettering Cancer Center | 2024-09-12 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (NCT06150040) | Centre Leon Berard | 2024-09-11 |
| A Study of SIPLIZUMAB in AILD and LT Patients (NCT06455280) | Elizabeth C. Verna | 2024-09-11 |
| A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects. (NCT05620940) | Inventage Lab., Inc. | 2024-09-11 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (NCT06487559) | AbbVie | 2024-09-11 |
| A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants (NCT06571266) | AbbVie | 2024-09-11 |
| ABA-101 in Participants With Progressive Multiple Sclerosis (NCT06566261) | Abata Therapeutics | 2024-09-11 |
| A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B (NCT06379789) | Regeneron Pharmaceuticals | 2024-09-11 |
| Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males (NCT06542237) | YourChoice Therapeutics, Inc. | 2024-09-11 |
| A Study of RAY1225 in Participants With Impaired Kidney Function (NCT06613763) | Guangdong Raynovent Biotech Co., Ltd | 2024-09-11 |
| Single Dose Texas 2017 (H3N2) Challenge Study (NCT06476275) | Duke University | 2024-09-11 |
| A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors (NCT06873555) | Heronova Pharmaceuticals | 2024-09-11 |
| Prevention of Progression of Prediabetes, Obesity and CV Risk (NCT06446531) | The University of Texas Health Science Center at San Antonio | 2024-09-11 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (NCT06540066) | BeiGene | 2024-09-11 |
| Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors (NCT06596915) | Shandong Boan Biotechnology Co., Ltd | 2024-09-11 |
| TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer (NCT06532799) | Essen Biotech | 2024-09-10 |
| A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma (NCT06586294) | Akeso | 2024-09-10 |
| PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT06590194) | Suzhou Puhe Pharmaceutical Technology Co., LTD | 2024-09-10 |
| Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents (NCT06588504) | Novo Nordisk A/S | 2024-09-10 |
| Cannabis and Opioid Use Disorder (NCT05729932) | Shanna Babalonis, PhD | 2024-09-10 |
| A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883. (NCT06586216) | Pfizer | 2024-09-10 |
| A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) (NCT06817343) | Exegenesis Bio | 2024-09-10 |
| Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (NCT06394570) | University of Texas Southwestern Medical Center | 2024-09-10 |